ResMed Inc (BSP:R1MD34)
R$ 381 9.84 (2.65%) Market Cap: 223.72 Bil Enterprise Value: 226.25 Bil PE Ratio: 32.98 PB Ratio: 7.04 GF Score: 86/100

Resmed Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2023 / 02:50PM GMT
Release Date Price: R$287.97
Sean M. Laaman
Morgan Stanley, Research Division - Australian Healthcare Analyst

Good morning, everyone. I'm Sean Laaman, the Australian Healthcare Analyst here at Morgan Stanley. I'm joined on stage from ResMed, Mick Farrell, CEO; and Brett Sandercock, CFO. So welcome, gentlemen, and thank you for your time today.

Questions & Answers

Sean M. Laaman
Morgan Stanley, Research Division - Australian Healthcare Analyst

Maybe just to kick things off, pandemic, hopefully, well in the rear vision mirror by now. So how would you describe the patient volumes and the market growth compared to 2019 as a jumping off point?

Michael J. Farrell
ResMed Inc. - CEO & Chairman

Yes, good question. And -- so we're looking very much at the patient flows, and using 2019 as the base of pre-COVID, and we're seeing triple digits. So 105%, 109%, 115%, all the 140 countries that we're operating in. China, we had the most recent shutdown part, which was sort of 6, 9 months ago now, but even that's sort of flowing through the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot